Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.79 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952057 | 1.00 | ADRB2 (0.79) | ADRB2CHRM3ADRB1 | |
| SCHEMBL5038665 | 0.96 | ADRB2 (0.82) | ADRB2CHRM3ADRB1 | |
| SCHEMBL5038663 | 0.96 | ADRB2 (0.82) | ADRB2CHRM3ADRB1 | |
| SCHEMBL5038637 | 0.93 | ADRB2 (0.82) | ADRB2CHRM3ADRB1 | |
| SCHEMBL5038638 | 0.93 | ADRB2 (0.82) | ADRB2CHRM3ADRB1 | |
| SCHEMBL14451871 | 0.90 | ADRB2 (0.82) | ADRB2CHRM3 | |
| SCHEMBL5037145 | 0.89 | ADRB2 (0.70) | ADRB2CHRM3ADRB1 | |
| SCHEMBL5037141 | 0.89 | ADRB2 (0.70) | ADRB2CHRM3ADRB1 | |
| SCHEMBL5037072 | 0.88 | ADRB2 (1.00) | ADRB2CHRM3 | |
| SCHEMBL5037075 | 0.88 | ADRB2 (1.00) | ADRB2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1708991-B1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2007-10-17 | — | — | EP | claimed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | claimed |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | PFIZER INC. | 2005-08-18 | — | — | US | claimed |
| US-7767715-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090197912-A1 | Sulfonamide Derivatives for the Treatment of Diseases | BROWN ALAN DANIEL | 2009-08-06 | — | — | US | disclosed |
| US-7528170-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080267970-A1 | Sulfonamide Derivatives For The Treatment of Diseases | BROWN ALAN DANIEL | 2008-10-30 | — | — | US | disclosed |
| US-20080193988-A1 | Such as 2-(3-{2-[((2R)-2-{4-Benzyloxy-3-[(dimethylsulfonyl)amino]phenyl}-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}phenyl)-N-[(4'-hydroxybiphenyl-3-yl)methyl]-acetamide | GLADWELL IAIN ROBERT | 2008-08-14 | — | — | US | disclosed |
| EP-1708991-B1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | PFIZER INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197912-A1 | Sulfonamide Derivatives for the Treatment of Diseases | SULT2A1, STS, SULT1A1 | ADRB2 2148/4885CHRM3 1774/4885ADRB1 2216/4885 |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | LTC4S, LTB4R2, LTB4R | ADRB2 119/4885CHRM3 29/4885ADRB1 94/4885 |
| US-20080267970-A1 | Sulfonamide Derivatives For The Treatment of Diseases | SULT2A1, STS, SULT1A1 | ADRB2 2148/4885CHRM3 1774/4885ADRB1 2216/4885 |
| US-20080193988-A1 | Such as 2-(3-{2-[((2R)-2-{4-Benzyloxy-3-[(dimethylsulfonyl)amino]phenyl}-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}phenyl)-N-[(4'-hydroxybiphenyl-3-yl)methyl]-acetamide | NR4A1, CYP2A6, GPR6 | ADRB2 118/4885CHRM3 257/4885ADRB1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.